For instance, we encapsulated the therapeutic antibody rituximab (RTX) that targets CD20 of B-cell lymphoma into MPC nanocapsules with degradable crosslinkers, followed by conjugation of CXCL13 as a ligand (nRTXCXCL13) on the surface to target B-cell lymphomas (Wen et al., 2019). This evidence concerns the gene CXCL13 and B-cell non-Hodgkin lymphoma.